Skip to content
DataLookout
Menu

NCT05676450

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 8 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2028
    • Eligibility criteria expanded, about 5 words
    • Study description expanded, about 2 words
  2. Minor Site contacts updated at 1 of 2 sitesv10
  3. Minor Site contacts updated at 2 of 2 sitesv8
  4. Notable Primary completion date: Aug 31, 2024 to Aug 31, 2026
    • Site contacts updated at 2 of 2 sites
    v7
  5. Minor Study sites: 1 to 2v5
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Start date: Feb 2, 2023 to Feb 23, 2023v3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study completion date: Aug 31, 2024 to Aug 31, 2026
    • Start date changed from estimate of May 1, 2023 to Feb 2, 2023
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival (OS)
Timeframe: through study completion; an average 1 year

Arms and interventions

cell-free DNA (cfDNA) samplesOther

cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method. Blood will be drawn 3 times (by vein)

Diagnostic tests: cell-free DNA

Sites

2 sites in 1 country